Publications
Shah NP. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia. Clinical advances in hematology & oncology : H&O. 2011. PMID: 22252660
Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B. IL-10 and IL-10 receptor defects in humans. Annals of the New York Academy of Sciences. 2011. PMID: 22236434
Kohlwes RJ, Cornett P, Dandu M, Julian K, Vidyarthi A, Minichiello T, Shunk R, Jain S, Harleman E, Ranji S, Sharpe B, O'Sullivan P, Hollander H. Developing educators, investigators, and leaders during internal medicine residency: the area of distinction program. Journal of graduate medical education. 2011. PMID: 23205204
Laponis R, O'Sullivan PS, Hollander H, Cornett P, Julian K. Educating generalists: factors of resident continuity clinic associated with perceived impact on choosing a generalist career. Journal of graduate medical education. 2011. PMID: 23205193
Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. British journal of cancer. 2011. PMID: 22127285
Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. British journal of cancer. 2011. PMID: 22127285
Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. British journal of cancer. 2011. PMID: 22127285
Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for height and its components: analyses from the Breakthrough Generations Study. American journal of human biology : the official journal of the Human Biology Council. 2011. PMID: 22121080
Daud AI. BEAM trial: lighting the way ahead? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. PMID: 22124100
Catherine C. Smith, Jason Chin, Qi Wang, Sara Salerno, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, Alexander E Perl, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, John Kuriyan, Neil Shah. Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia. Blood. 2011. PMID:
Jorge E. Cortes, Alexander E Perl, Catherine C. Smith, Tibor Kovacsovics, Herve Dombret, Hartmut Dohner, Bjorn Steffen, Arnaud Pigneux, Philippe Rousselot, Juergen Krauter, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Anthony D. Ho, Norbert Ifrah, Theo de Witt, Robert Corringham, Joyce James, David Lilienfeld, Eugen Leo, Guy Gammon, Mark J. Levis. A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results. Blood. 2011. PMID:
Francisco Valles, Samuel Regalado, James L. Rubenstein, Soonmee Cha. Combined Diffusion and Perfusion MRI As Biomarkers of Prognosis in Immunocompetent Patients with Primary CNS Lymphoma. Blood. 2011. PMID:
Warren Fiskus, Catherine C. Smith, Jacqueline Smith, Scott C. Wise, Elisabeth Lasater, Lauren E. Damon, Sara Salerno, Allan Fleming, Ruben Reyes, Siddhartha Ganguly, Mark S. Berger, Tom J. Rutkoski, Joseph McGuirk, Neil Shah, Kapil N. Bhalla. Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations. Blood. 2011. PMID:
Cigall Kadoch, Valerie Wong, Lingjing Chen, Anna Bet-Lachin, Ritu Roy, William Hyun, Caroline Behler, Clifford Lowell, James L. Rubenstein. Dynamic Changes in Macrophage Polarization Correlate with Progression and Response in CNS Lymphoma: Insights Into the Transcriptome of Lymphoma-Associated M2 Macrophages,. Blood. 2011. PMID:
Catherine C. Smith, Lauren E. Damon, Xiaotian Zhu, Sara Salerno, Neil Shah. Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants. Blood. 2011. PMID:
Hua-Xin Gao, Shawn Anderson, Lingjing Chen, Cigall Kadoch, Byron C Hann, Clifford Lowell, Colin Collins, James L. Rubenstein. Genomic and Molecular Properties of Relapsed CNS Lymphoma Using Novel Primary Meningeal Lymphoma Cell Lines and Intracranial Xenografts,. Blood. 2011. PMID:
Catherine C. Smith, Alexander E Perl, Elisabeth Lasater, Chao Zhang, Grace R Jeschke, Lauren E. Damon, Martin Carroll, Neil P. Shah. PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro. Blood. 2011. PMID:
Anna Bet-Lachin, Frank Jiang, Lingjing Chen, Keyvan Keshari, David Wilson, John Kurhanewicz, James L. Rubenstein. Metabolic Profiling of CNS Lymphoma and Its Microenvironment. Blood. 2011. PMID:
Alexander E Perl, Grace R Jeschke, Catherine C. Smith, James K. Mangan, Selina M. Luger, Martin Carroll. Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,. Blood. 2011. PMID:
James L. Rubenstein, Lingjing Chen, Ranjana Advani, Jan Drappatz, Elizabeth Gerstner, Tracy Batchelor, Hendrikus Krouwer, Cigall Kadoch, Pamela Munster, Soonmee Cha, Marc A Shuman, Lloyd E. Damon. Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. Blood. 2011. PMID: